Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

November 13, 2019 Capital Markets and Public M&A

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

The subscription price was determined to SEK 16 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates. 
Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Stephanie Stiernstedt.

 

Related

Vinge advises Axcel in connection with the launch of Accru Partners, a new group within accounting, tax, audit and advisory services

Vinge has advised the Nordic private equity firm Axcel in connection with its establishment of Accru Partners, a new group of 22 independent firms in Sweden within accounting, tax, audit and other advisory services.
October 04, 2024

Vinge advises Irisity in connection with issue of units

Vinge advises Irisity AB (publ) in connection with its rights issue of units consisting of shares and warrants. The issue is guaranteed to 80 per cent through subscription commitments and external guarantors.
October 03, 2024

Vinge has advised the municipality of Varberg in legal proceedings regarding a detailed development plan for a new residential area

The detailed development plan for approximately 50 new homes in Trönningenäs, north of the city of Varberg, was adopted by the municipality on 23 February 2023. It was subsequently appealed in several stages. By decision of the Land and Environment Court of Appeal, the plan become legally binding on 2 October 2024.
October 03, 2024